Metastatic Castration-resistant Prostate Cancer Clinical Trials in Seattle, Washington

5 studies are recruiting for metastatic castration-resistant prostate cancer in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

   This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Harborview Medical Center, Seattle, Washington

   Locations

   236 in total

   Run by

   Pfizer

   See if you can join NCT06629779 on ClinicalTrials.gov

2. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Swedish Cancer Institute, Seattle, Washington

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

3. A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

   The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior secon…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   23 in total

   Run by

   Kyntra Bio

   See if you can join NCT06842498 on ClinicalTrials.gov

4. A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

   The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   15 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06067841 on ClinicalTrials.gov

5. ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

   This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. Th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Seattle Cancer Care Alliance, Seattle, Washington

   Locations

   31 in total

   Run by

   Zenith Epigenetics

   See if you can join NCT04986423 on ClinicalTrials.gov